SANFER ACQUIRES MAJORITY STAKE IN PROBIOMED
The alliance between the two companies through the operation celebrated last Thursday, May 12th, represents a new era for the pharmaceutical industry in Mexico and Latin America.
Mexico City, May 19th, 2022 – PROBIOMED, a company mainly dedicated to the manufacture of biotechnological drugs and medicines, announces the purchase of a majority shareholding by SANFER PHARMA.
With the acquisition of PROBIOMED by SANFER, one of the largest pharmaceutical groups in Mexico and Latin America, the latter ventures into the field of biotechnology and strengthens its broad portfolio of products for the benefit of patients, physicians and institutions by making treatments with a high degree of quality and innovation available to them.
The above aims, through the manufacture of biopharmaceutical drugs and medicines in Mexico, to significantly reduce the prevailing technological dependency in our country regarding this class of products, substitute imports and strengthen the current PROBIOMED platform so that these medicines are available in most Latin American countries.
As part of SANFER Group, and backed by its international prestige, it is envisaged that PROBIOMED can establish in the short term trade and technology transfer agreements that will make it possible for state-of-the-art biotechnological products to arrive in Mexico.
The injection of capital that SANFER is carrying out will allow the relaunch of PROBIOMED to the market with greater financial solvency to start a new stage, in which it is sought that the sum of the strengths of these pharmaceutical companies will promote the growth of both enterprises, reiterating their commitment with their collaborators, suppliers, communities, prescribing physicians, patients, shareholders and other interest groups, and of course, with the health of Mexico and the world.
PROBIOMED thanks SANFER PHARMA shareholders for their trust in carrying out this corporate alliance, as well as the group of bankers, lawyers and advisors who accompanied the transaction until its completion.
ABOUT PROBIOMED
PROBIOMED is a Mexican biopharmaceutical company focused on research, development, manufacturing and marketing of pharmaceutical products for human health. We employ more than 800 men and women and operate 3 manufacturing plants that comply with the strictest national and international regulations.
Since our foundation, in 1970, we have worked to provide high-tech solutions that help improve the health and quality of life of millions of patients by bringing them generic chemically synthesized and biotechnological medicines for the prevention and treatment of chronic-degenerative diseases of great social and economic impact such as rheumatoid arthritis, multiple sclerosis, chronic kidney failure and various types of cancer, among other conditions.
Press contact: comunicacioncorporativa@probiomed.com.mx
ABOUT SANFER
SANFER Global commercializes prescription and OTC medicines for human health, as well as veterinary products. It has more than 7 thousand collaborators in Mexico and Latin America and operations in more than 40 countries. Its strategy, since its foundation, has focused on maintaining constant growth through investments in infrastructure and the acquisition of brands and companies to consolidate its leadership in the pharmaceutical industry. SANFER Pharma, SANFER Animal Health, Aerobal, Bussié, Hormona, Grimann, Portugal Group, Inafarma, Labinco, Litogrimann, Pasteur, PharmaDorf and PROBIOMED are companies of SANFER Group.
Press contact: comunicacioncorporativa@sanfer.com.mx
